On 1 February 2019, the company (CTI BioPharma) announced that the they will withdraw its European Marketing Authorization Application (MAA) for pacritinib. This is because the company learned from the regulator that it is likely to formally adopt a negative opinion in its evaluation of pacritinib for this indication. Therefore, this appraisal will be suspended. We will continue to monitor any developments and will update stakeholders if the situation changes.